SAFETY OF USING METHOTREXATE SOLUTION FOR SUBCUTANEOUS INJECTIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS
https://doi.org/10.14412/1995-4484-2015-371-374
Abstract
Objective: to evaluate the safety of treatment with methotrexate (MT) solution for subcutaneous injections in patients with rheumatoid arthritis (RA).
Subjects and methods. 237 RA patients enrolled in the study within the REMARCA protocol were given MT solution for subcutaneous injections (Metoject) to assess the standard parameters of therapy safety.
Results. Overall, adverse events (AE) were noted in 49 (21%) patients. In 30 (30%) of them RA duration was less than 6 months (Group 1) and in 19 (14%) – more than 6 months (Group 2), in most cases average MT dose was 20.9±3.45 mg/week. Elevation of alanine aminotransferase and aspartate aminotransferase levels, nausea, postinjection reactions, alopecia, rash, infections, and leukopenia, were common (> 1%, but <10%); diarrhea, metallic taste in the mouth, soft tissue abscess/infiltration developing far from the injection site, were uncommon (the WHO term corresponding to 0.1–1%). AE required MT discontinuation in 4.2% of the patients.
Conclusion. The results of the study allow discussing subcutaneous MT administration before treatment with biologicals, which makes it possible not only to reduce financial expenditures, but also to improve patient safety
About the Authors
Yu. V. Muravyev
V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia 34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
Russian Federation
G. I. Gridneva
V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia 34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
Russian Federation
D. E. Karateev
V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia 34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
Russian Federation
E. L. Luchichina
V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia 34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
Russian Federation
References
1. Visser K, Katchhamart W, Losa E, et al. Multinational evidencebased recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systemic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiatiive. Ann Rheum Dis. 2009;68:1086–93. doi: http://dx.doi.org/10.1136/ard.2008.094474
2. Todoerti M, Maglione W, Bernero E, et al. Systemic review of 2008–2012 literature and update of recommendations for the use of methotrexate in rheumatic disease, with focus one rheumatoid arthritis. Rheumatismo. 2013;65:207–18.
3. Hoekstra M, Haagsma C, Neef C, et al. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol. 2004;31(4):645–8.
4. Braun J, Kä stner P, Flaxenberg P, et al.; MCMTX. 6/RHStudyGroup. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008;58(1):73–81. doi: 10.1002/art.23144
5. Каратеев ДЕ, Лучихина ЕЛ, Муравьев ЮВ и др. Первое российское стратегическое исследование фармакотерапии ревматоидного артрита (РЕМАРКА). Научно-практическая ревматология. 2013;51(2):117–25 [Karateev DE, Luchikhina EL, Muravyev YuV, et al. The first russian strategic study of pharmacotherapy for rheumatoid arthritis (REMARCA). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2013;51(2):117–25 (In Russ.)].
6. Муравьев ЮВ. Нежелательные реакции при применении ритуксимаба. В кн.: Насонов Е.Л., редактор. Анти-В- клеточная терапия в ревматологии: фокус на ритуксимаб. Москва: ИМА-ПРЕСС; 2012. С. 258–94 [Murav'ev YuV. Adverse reactions in the application of rituximab. In: Nasjnjv EL, editor. Anti-B-kletochnaya terapiya v revmatologii: fokus na rituksimab [Anti-B-cell therapy in rheumatology: a focus on rituximab]. Moscow: IMA-PRESS; 2012. P. 258–94].
7. Ioannidis JP, Evans SJ, Gotzsche PC, et al.; CONSORT Group. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004 Nov 16;141(10):781–8. doi: 10.7326/0003-4819-141-10-200411160-00009
8. Woodworth T, Furst DE, Alten R, et al. Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the Rheumatology Common Toxicity Criteria v.2.0. J Rheumatol. 2007;34(6):1401–14.
9. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45. doi: 10.1038/clpt.1981.154
10. Osman A, Mulherin D. Is parenteral methotrexate worth trying? Ann Rheum Dis. 2001;60(4):432. doi: 10.1136/ard.60.4.432
11. Bharadwaj A, Agrawal S, Batley M, Hammond A. Use of parenteral methotrexate significantly reduces the need for biological therapy. Rheumatology. 2008;47:222. doi: 10.1093/rheumatology/kem306
12. Erkeller-Yuksel FM, Griffin AJ. Parenteral methotrexate really works. Ann Rheum Dis. 2003;61 Suppl. 1:209.
13. Griffin AJ, Erkeller-Yuksel F. Parenteral methotrexate should be given before biological therapy. Rheumatology. 2004;43:678. doi: 10.1093/rheumatology/keh110
14. Wegrzyn J, Adeleine P, Miossec P. Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis. Ann Rheum Dis. 2004;63:1232–4. doi: 10.1136/ard.2003.011593
15. Ward J, Ong V, Hibbitt J, Steuer A. Parenteral methotrexate in active rheumatoid arthritis: a prerequisite for use of biologic agents? Rheumatology. 2007;46 Suppl 1:i31–2.
16. Thornton C, Ong V, Ward J, et al. Comment on: Use of parenteral methotrexate significantly reduces the need for biological therapy. Rheumatology. 2008;47(9):1438. doi: 10.1093/rheumatology/ken250
17. Schiff MH, Jaffe JS, Freundlich B. Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration. Ann Rheum Dis. 2014;73(8):1549–51. doi: 10.1136/annrheumdis-2014-205228
18. Freundlich B, Kivitz A, Jaffe JS. Nearly pain-free self-administration of subcutaneous methotrexate with an autoinjector: results of a phase 2 clinical trial in patients with rheumatoid arthritis who have functional limitations. J Clin Rheumatol. 2014 Aug;20(5):256–60. doi: 10.1097/RHU.0000000000000117
19. Hassanzadeh R, Mangan C, France J, Bawa S. Subcutaneous methotrexate to cut costs? J Rheumatol. 2012 Aug;39(8):1764–5. doi: 10.3899/jrheum.120091
Review
For citations:
Muravyev Yu.V., Gridneva G.I., Karateev D.E., Luchichina E.L. SAFETY OF USING METHOTREXATE SOLUTION FOR SUBCUTANEOUS INJECTIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS. Rheumatology Science and Practice. 2015;53(4):371-374. (In Russ.) https://doi.org/10.14412/1995-4484-2015-371-374
Views:
2190
Email this article 